Absci Secures $100M Boost as Phase 1 Data Shows Promise for Hair Loss Drug
Event summary
- Absci reported positive interim Phase 1 data for ABS-201, showing favorable safety and a half-life of at least 65 days.
- Completed $100M underwritten offering, including $40M strategic investment from Eli Lilly & Company.
- Cash runway extended to second half of 2028 following the funding round.
- Anticipates interim proof-of-concept data for pattern hair loss in second half of 2026 and full readout in early 2027.
The big picture
Absci's $100M funding round, bolstered by Eli Lilly's strategic investment, underscores growing confidence in AI-driven drug discovery. The positive Phase 1 data for ABS-201 positions the company to potentially redefine treatment paradigms for pattern hair loss and endometriosis, addressing significant unmet medical needs. The extended cash runway provides a buffer for clinical advancements, but execution risks remain as Absci navigates multiple pipeline programs.
What we're watching
- Clinical Milestones
- Whether ABS-201 can deliver on interim proof-of-concept data for pattern hair loss by year-end and full readout in early 2027.
- Strategic Partnerships
- How Eli Lilly's $40M investment and advisory board participation will influence Absci's endometriosis program strategy.
- Financial Sustainability
- The pace at which Absci can maintain its cash runway into 2028 while advancing multiple pipeline programs.
Related topics